Preliminary safety results of an ongoing phase I/II clinical study of MGN1601, a tumor vaccine comprising allogeneic, gene-modified, and irradiated tumor cells in combination with an immunomodulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results